Ravidasvir – a pan-genotypic NS5A inhibitor for the treatment of chronic hepatitis C

Authors:

Abstract
Chronic hepatitis C (CHC) is a viral disease primarily affecting the liver, characterized by prolonged persistence of hepatitis C virus (HCV) and a high risk of developing liver cirrhosis and hepatocellular carcinoma. Modern direct-acting antiviral agents achieve a sustained virologic response in over 95% of patients, with good tolerability and safety. The aim of this study is to review the characteristics, efficacy, and safety of ravidasvir, a next-generation antiviral drug for the treatment of CHC. The literature search was conducted in PubMed/MEDLINE, Embase, and ClinicalTrials.gov up to August 11, 2025, using the keywords: ravidasvir, NS5A inhibitor, HCV, Hepatitis C, efficacy, safety. The review included phase I–III clinical trials investigating ravidasvir in CHC. Ravidasvir is a pan-genotypic inhibitor of the hepatitis C virus nonstructural protein 5A (NS5A), developed as an affordable alternative to other direct-acting antiviral agents. Ravidasvir has been studied as part of interferon-free oral regimens containing sofosbuvir or danoprevir boosted with ritonavir, with or without ribavirin. Clinical trial results have demonstrated high efficacy of ravidasvir-containing regimens against HCV genotypes 1, 3, and 4, regardless of HIV co-infection, prior interferon-based treatment experience, or compensated liver cirrhosis. Thus, ravidasvir demonstrates high efficacy against HCV and an optimal safety and tolerability profile, making it a reliable directacting antiviral agent for the treatment of CHC, including in hard-to-treat patient populations. Key words: hepatitis C virus, chronic hepatitis C, NS5A protein, treatment, ravidasvir